Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$766M |
| 2 |
Adobe
ADBE
|
$529M |
| 3 |
Merck
MRK
|
$463M |
| 4 |
Tesla
TSLA
|
$359M |
| 5 |
AGN
Allergan plc
AGN
|
$339M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$714M |
| 2 |
Gilead Sciences
GILD
|
$600M |
| 3 |
Perrigo
PRGO
|
$585M |
| 4 |
EMC
EMC CORPORATION
EMC
|
$448M |
| 5 |
Morgan Stanley
MS
|
$423M |
Sector Composition
| 1 | Healthcare | 17.95% |
| 2 | Consumer Discretionary | 15% |
| 3 | Communication Services | 10.58% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
Xoma
XOMA
$426M
| $11.6M | 0.01% |
+86,139
| New | +$11.6M |
|
477
SPDR S&P 500 ETF Trust
SPY
$660B
| $11.5M | 0.01% |
62,508
+28,208
| +82% | +$5.21M |
|
478
Douglas Emmett
DEI
$2.83B
| $11.5M | 0.01% |
494,469
-20,009
| -4% | -$466K |
|
479
MPLX
MPLX
$51.5B
| $10.8M | 0.01% |
242,686
+2,482
| +1% | +$111K |
|
|
KIN
480
DELISTED
Kindred Biosciences, Inc.
KIN
| $10M | 0.01% |
+901,774
| New | +$10M |
|
|
CMRX
481
DELISTED
Chimerix, Inc.
CMRX
| $9.94M | 0.01% |
657,558
+424,770
| +182% | +$6.42M |
|
|
TTPH
482
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $9.78M | 0.01% |
36,175
-9,899
| -21% | -$2.68M |
|
|
VIAB
483
DELISTED
Viacom Inc. Class B
VIAB
| $9.41M | 0.01% |
107,766
-60,318
| -36% | -$5.27M |
|
|
MKTO
484
DELISTED
MARKETO INC COM STK (DE)
MKTO
| $9.07M | 0.01% |
+244,586
| New | +$9.07M |
|
|
PKY
485
DELISTED
Parkway, Inc.
PKY
| $9M | 0.01% |
+466,560
| New | +$9M |
|
|
ATHL
486
DELISTED
ATHLON ENERGY INC COM
ATHL
| $8.95M | 0.01% |
295,818
+218
| +0.1% | +$6.59K |
|
|
PLG
487
Platinum Group Metals
PLG
$186M
| $8.75M | 0.01% |
74,749
| – | – |
|
|
EQM
488
DELISTED
EQM Midstream Partners, LP
EQM
| $8.58M | 0.01% |
145,880
+1,891
| +1% | +$111K |
|
|
NTLS
489
DELISTED
NTELOS HLDGS CORP COM
NTLS
| $7.89M | 0.01% |
389,793
-641,906
| -62% | -$13M |
|
490
Qualys
QLYS
$4.87B
| $7.42M | 0.01% |
+321,218
| New | +$7.42M |
|
491
Agios Pharmaceuticals
AGIO
$2.09B
| $7.36M | 0.01% |
307,235
+132,235
| +76% | +$3.17M |
|
|
YOKU
492
DELISTED
YOUKU TUDOU INC.(CAYMAN ISLS)
YOKU
| $7.3M | 0.01% |
240,797
+18,839
| +8% | +$571K |
|
|
PSXP
493
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $7.21M | 0.01% |
189,998
+2,229
| +1% | +$84.6K |
|
|
FURX
494
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
| $7.12M | 0.01% |
+169,407
| New | +$7.12M |
|
495
Corcept Therapeutics
CORT
$7.31B
| $6.91M | 0.01% |
2,144,742
+7,993
| +0.4% | +$25.7K |
|
|
ANAC
496
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $6.44M | 0.01% |
+383,700
| New | +$6.44M |
|
497
Exxon Mobil
XOM
$466B
| $6.16M | 0.01% |
60,853
-1,570
| -3% | -$159K |
|
498
Verastem
VSTM
$663M
| $5.72M | 0.01% |
41,830
+163
| +0.4% | +$22.3K |
|
|
HSTO
499
DELISTED
Histogen Inc. Common Stock
HSTO
| $5.47M | 0.01% |
4,238
+13
| +0.3% | +$16.8K |
|
500
Marcus & Millichap
MMI
$1.29B
| $5.37M | 0.01% |
+360,630
| New | +$5.37M |
|